TSG101 antibody (AA 223-257) (FITC)
Quick Overview for TSG101 antibody (AA 223-257) (FITC) (ABIN8051704)
Target
See all TSG101 AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- AA 223-257
-
Purpose
- Anti-TSG101 Antibody FITC Conjugated
-
Cross-Reactivity (Details)
- No cross-reactivity with other proteins.
-
Purification
- Immunogen affinity purified.
-
Immunogen
- E.coli-derived human TSG101 recombinant protein (Position: E223-K257).
-
Isotype
- IgG
-
-
-
-
Application Notes
- Flow Cytometry, Optimal dilutions should be determined by end users.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Buffer
- Each vial contains 50 % glycerol, 0.9 % NaCl, 0.2 % Na2HPO4, 0.02 % Sodium azide.
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Storage
- -20 °C
-
Storage Comment
- At -20°C for one year from date of receipt. Avoid repeated freezing and thawing. Protect from light.
-
Expiry Date
- 12 months
-
-
- TSG101 (Tumor Susceptibility Gene 101 (TSG101))
-
Alternative Name
- TSG101
-
Background
-
Background: TSG101, known as Tumor susceptibility gene 101, is mapped to 11p15. The protein encoded by this gene belongs to a group of apparently inactive homologs of ubiquitin-conjugating enzymes. The gene product contains a coiled-coil domain that interacts with stathmin, a cytosolic phosphoprotein implicated in tumorigenesis. And the protein may play a role in cell growth and differentiation and act as a negative growth regulator. In vitro steady-state expression of this tumor susceptibility gene appears to be important for maintenance of genomic stability and cell cycle regulation. Mutations and alternative splicing in this gene occur in high frequency in breast cancer and suggest that defects occur during breast cancer tumorigenesis and/or progression.
Gene Full Name: tumor susceptibility 101
-
Gene ID
- 7251
-
UniProt
- Q99816
Target
-